171 related articles for article (PubMed ID: 2018816)
1. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
2. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
[TBL] [Abstract][Full Text] [Related]
4. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.
Mueller EA; Murphy DL; Sunderland T
Psychopharmacology (Berl); 1986; 89(3):388-91. PubMed ID: 3014595
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
[TBL] [Abstract][Full Text] [Related]
6. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
[TBL] [Abstract][Full Text] [Related]
7. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Zohar J; Insel TR
Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Khanna S; John JP; Reddy LP
Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
[TBL] [Abstract][Full Text] [Related]
10. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
[TBL] [Abstract][Full Text] [Related]
11. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
[TBL] [Abstract][Full Text] [Related]
12. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
[TBL] [Abstract][Full Text] [Related]
13. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
de Leeuw AS; Westenberg HG
J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
[TBL] [Abstract][Full Text] [Related]
16. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
[TBL] [Abstract][Full Text] [Related]
17. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
Bastani B; Nash JF; Meltzer HY
Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
[TBL] [Abstract][Full Text] [Related]
18. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.
Kahn RS; Kalus O; Wetzler S; Cahn W; Asnis GM; van Praag HM
Psychiatry Res; 1990 Aug; 33(2):189-98. PubMed ID: 2243896
[TBL] [Abstract][Full Text] [Related]
19. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats.
Aulakh CS; Hill JL; Murphy DL
J Pharmacol Exp Ther; 1992 Nov; 263(2):588-95. PubMed ID: 1432690
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
